Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br ASK in multiple sclerosis and
2024-07-01
ASK1 in multiple sclerosis and optic neuritis Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system (CNS), is the most common neurological disease among young adults in the United States and Europe (Dutta and Trapp, 2011). Although MS primarily affect
-
Although the gene that encodes DHFR has been strongly conser
2024-06-28
Although the gene that encodes DHFR has been strongly conserved during evolution, subtle differences in the active sites of bacterial, human and parasite phospholipase inhibitor have been exploited to develop DHFR inhibitors specific to particular pathogens 1, 3. For example, pyrimethamine and cycl
-
In addition AMPK reduces protein synthesis and stimulates ap
2024-06-28
In addition, AMPK reduces protein synthesis and stimulates apoptotic and autophagic pathways through the inhibition of the mechanistic target of rapamycin (mTOR), which regulates cellular metabolic homeostasis, insulin secretion, insulin resistance, autophagy and apoptosis (Maiese, 2016). mTOR is th
-
smad pathway Compelling evidence now indicates that DR
2024-06-28
Compelling evidence now indicates that DR is a multifactorial disease that involves chronic inflammation at every stage, from initiation to progression and eventually to ischemia and NV [6,7]. Data from animal studies suggest that leukocyte-endothelial cell adhesion and entrapment (leukostasis) are
-
br Experimental Procedures br Acknowledgments
2024-06-28
Experimental Procedures Acknowledgments We thank the members of the Qing laboratory for helpful suggestions and Biotree Biotech Co., Ltd. (Shanghai, China) for metabolomics analysis and data interpretation. This study was supported by the National Key Research and Development Program of China
-
Preclinical models indicate roles for adiponectin in the mai
2024-06-28
Preclinical models indicate roles for adiponectin in the maintenance of hepatic lipid metabolism. Adiponectin overexpression prevents accumulation of triglycerides or the deleterious lipid metabolites diacylglycerols or ceramides [5,8]. Direct manipulation of adiponectin expression demonstrates a po
-
ASC-J9 synthesis br Expression of ADK in
2024-06-28
Expression of ADK in the normal brain In adult brain, ADK is primarily expressed in astrocytes. Immunocytochemical analysis of adult rat and mouse ASC-J9 synthesis revealed predominant astrocytic expression throughout the hippocampus and cortex. Two isoforms of ADK have been identified in mammals
-
The structure of LO is divided in two
2024-06-28
The structure of 5-LO is divided in two domains, the catalytic C-terminal domain and the N-terminal regulatory C2-like domain (C2ld) [59,60]. The C2ld spans the Triamcinolone synthesis 1-114 and is responsible for translocation and binding of calcium and membranes [61–63]. The catalytic domain is p
-
The subdivision of HT receptors started in the s
2024-06-28
The subdivision of 5-HT receptors started in the 1950s by Gaddum and colleagues, when they realised that in the guinea pig ileum, the effects of 5-HT could be blocked in part by morphine (M), and in part by dibenzyline (D). Gaddum and Picarelli proposed two receptor classes, 5-HT M and 5-HT D (1957)
-
The relatively high concentration of
2024-06-28
The relatively high concentration of 5-HT used in this study (100 µM) is consistent with the concentrations used in other published ex vivo studies (Ropert and Guy, 1991, Passani et al., 1994, Shen and Andrade, 1998). In our paradigm 5-HT was focally applied at the surface of the slice via a fast pe
-
br Conclusions br Conflicts of interest br Acknowledgements
2024-06-28
Conclusions Conflicts of interest Acknowledgements This work was supported by Ege University Research Fund [BAP, 14-ECZ-030, 2016]. Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, sp
-
In this report the natural compound deguelin potently
2024-06-27
In this report, the natural compound deguelin potently and dose-dependently suppressed Aurora B kinase activity in vitro, indicating that this compound is an effective Aurora B inhibitor. The docking study indicated that deguelin was docked into the ATP-binding pocket of Aurora B and formed hydropho
-
br Activity and expression of aromatase in the hippocampus T
2024-06-27
Activity and expression of aromatase in the hippocampus The brain, like the adrenals, gonads and the placenta, is a steroidogenic organ. This paradigm emerged from studies carried out as early as the 1980s by Baulieu and co-workers; these studies showed that steroids such as pregnenolone and dehy
-
Our surprising results show that AAD treated tumors adjacent
2024-06-27
Our surprising results show that AAD-treated tumors adjacent to adipose tissues and in steatotic liver continue to grow in the presence of a minimal number of microvessels. In non-adipose tumor models, the similar degree of vascular suppression is translated into marked suppression of tumor growth.
-
acetylcholine receptor br Eprosartan The AT R antagonist epr
2024-06-27
Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential acetylcholine receptor and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular
16325 records 124/1089 page Previous Next First page 上5页 121122123124125 下5页 Last page